Navigation Links
Sideeffects of Rosiglitazone in Type2 Diabetes Patients

The trade-offs between potential benefits and potential harms when rosiglitazone is used by people with type 2 diabetes has to be assessed .

This Cochrane Systematic Review analysed data from 18 trials that involved a total of 8432 people and found no evidence that rosiglitazone led to better patient outcomes when compared with other therapies.

Diabetic control (as measured by levels of HbA1c) was no better in patients given rosiglitazone when compared to other antidiabetic drugs. Patient oriented outcomes such as mortality, diabetes related morbidity, or quality of life were not addressed in most studies.

In addition to confirming the known risk of edema (people taking the treatment are at twice the risk of developing this condition) and an increase in body weight up to 5.0 kg, the authors found evidence from one large study indicating increased cardiovascular risk and an enhanced risk in women of having broken bones.

In people with type 2 diabetes, their body has a reduced ability to cause cells to remove glucose from the blood. The resulting high levels of blood-glucose can cause considerable damage especially to the eyes, nerves and kidneys.

Rosiglitazone is one of a range of drugs that increase cells sensitivity to insulin and therefore may restore some of the normal function.

Unfortunately, the published studies where people have taken rosiglitazone for at least 24 weeks do not give relevant data about issues like mortality, morbidity, and changes in health-related quality of life, says lead author Associate Professor Bernd Richter, who works at the Department of General Practice, in Duesseldorf.

Studies on patient-oriented outcomes are urgently needed, although it is questionable whether new studies with rosiglitazone will be ethical given the fact that less dangerous therapeutic alternatives exist, says Richter.


'"/>




Page: 1

Related medicine news :

1. Oral Drug Rosiglitazone Could Help Prevent Type 2 Diabetes
2. Patients Advised for Using Rosiglitazone to See Their Doctor - ADA
3. Less Information on Dietary Treatment in Type2 Diabetes
4. Alternative Option for Type2 Diabetes Treatment
5. Deep Insights into Type2 Diabetes by Wesley Researchers
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Thirty minutes of work up per day reduces the risk of Diabetes
9. Diabetes on the rise
10. Irregular Periods Linked to Diabetes
11. Cinnamon combats Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... and laboratory-grade deionized water from the same place. From 101 Water Texas, here ... Satisfaction: Patients and staff can enjoy a continuous supply of pure, fresh, oxygenated ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/22/2017)... PA (PRWEB) , ... April 22, 2017 , ... ... experience to his role as Vice President of Sales and Business Development at ... key GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: